DICE: DICE Therapeutics, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

DICE Therapeutics, Inc.

NASDAQ:DICE

SummaryFactSheetFinancial
Notice
Stock data is unavailable or the company’s delisted.
Price
$47.55
Loss Chance
58.4%
0.32JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Agile Therapeutics
NASDAQ:AGRX
2.68
$1.51
99.50%
Amphastar Pharmaceuticals
NASDAQ:AMPH
5.41
$20.53
68.59%
Assertio Holdings
NASDAQ:ASRT
2.33
$23.47
16.61%
biote Corp.
NASDAQ:BTMD
3.51
$2.43
37.33%
Collegium Pharmaceutical
NASDAQ:COLL
5.69
$34.34
90.09%
Jitta Factors
Growth Opportunity (4)
Recent Business Performance (19)
Financial Strength (36)
Return to Shareholders (1)
Competitive Advantage (8)
Jitta Signs
Recent IPOLess than 3 years
Operating MarginInconsistent
Recent Business PerformanceEarning decline 30.89% in the last year
Key Stats
Jitta Score
Jitta Line
0.32
100.00%
3.03
208.71%
3.05
163.37%
Pharmaceuticals
2.68
99.50%
5.41
68.59%
2.33
16.61%
COMPANY DESCRIPTION
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company’s lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California. As of August 9, 2023, DICE Therapeutics, Inc. operates as a subsidiary of Eli Lilly and Company.
www.dicetherapeutics.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.